Author(s):
Ruchika Namdev, Deepak Joshi, Vikas Jain, Ajay Sharma
Email(s):
ruchikanamdev2001@gmail.com
DOI:
10.52711/2321-5836.2024.00056 
Address:
Ruchika Namdev, Deepak Joshi, Vikas Jain, Ajay Sharma
Mahakal Institute of Pharmaceutical Studies, Ujjain 456664, Madhya Pradesh, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 4,
Year - 2024
ABSTRACT:
Type 2 diabetes mellitus (T2DM) is a persistent metabolic condition defined by insulin resistance and relative insulin insufficiency, frequently worsened by lifestyle elements. Brenzavvy, also known as Bexagliflozin, is a recently authorized medication tailored for managing T2DM. Its approval in the United States on January 20, 2023, marks it as an sodium-glucose co-transporter 2 inhibitor. This novel drug functions by inhibiting the sodium-glucose co-transporter 2, thereby enhancing glucose excretion in urine and reducing blood sugar levels. This review delves into Brenzavvy 's pharmacological attributes, clinical effectiveness, safety profile, and potential implications for T2DM treatment. Clinical trials have illustrated its efficacy in ameliorating glycemic control in T2DM patients, coupled with added advantages such as weight and blood pressure reduction. Overall, Brenzavvy represents a promising addition to the armamentarium of T2DM management, offering a novel approach to address hyperglycemia and associated metabolic abnormalities. Continued research and monitoring will further elucidate its role in enhancing patient outcomes and quality of life in the management of T2DM.
Cite this article:
Ruchika Namdev, Deepak Joshi, Vikas Jain, Ajay Sharma. Breaking Ground: A Review of Brenzavvy - The newly approved treatment for type 2 Diabetes mellitus. Research Journal of Pharmacology and Pharmacodynamics. 2024;16(4):328-1. doi: 10.52711/2321-5836.2024.00056
Cite(Electronic):
Ruchika Namdev, Deepak Joshi, Vikas Jain, Ajay Sharma. Breaking Ground: A Review of Brenzavvy - The newly approved treatment for type 2 Diabetes mellitus. Research Journal of Pharmacology and Pharmacodynamics. 2024;16(4):328-1. doi: 10.52711/2321-5836.2024.00056 Available on: https://rjppd.org/AbstractView.aspx?PID=2024-16-4-12
REFERENCE:
1. Jyoti Thakur. Effect of Maternal Diabetes on Fetus and Newborn. Asian J. Nursing Education and Research. 2019; 9(3): 463-465.
2. Lakshmi. K. Effectiveness of Nursing care of antenatal mothers with Gestational diabetes mellitus. Asian J. Nursing Education and Research. 2020; 10(3): 286-290.
3. Gepsi Jain, Nahomi Clement. A Study to assess the knowledge regarding self management behaviour among Type II Diabetes Mellitus patients in prevention of COVID-19 at selected area, Alappuzha District, Kerala, India. Asian Journal of Nursing Education and Research. 2022; 12(4): 449-3.
4. Preeti Tiwari. Antidiabetic Potential of Balarishta Prepared by Traditional and Modern Methods in Alloxan Induced Diabetic rats. Asian J. Research Chem. 2014; 7(7): 659-663.
5. Vasudevan N. J., Sara B. A Study to Assess the Effectiveness of Structured Teaching Programme on Knowledge regarding Management of Type 2 Diabetes Mellitus among Patients with Type 2 Diabetes Mellitus attending Diabetic OPD, RMMCH, Annamalai University. Int. J. Nur. Edu. and Research. 2014; 2(2): 113-116.
6. Pritam V. Gavit. Effectiveness of Buerger Allen exercise on Lower extremity perfusion among patients with type 2 Diabetes mellitus admitted at selected Hospitals of City. International Journal of Nursing Education and Research. 2021; 9(3): 305-9.
7. Flosy Rodrigues e Menezes. Diabetes Self-Management Education (DSME) effectiveness in people with Type 2 Diabetes Mellitus (T2DM)- A Systematic review. International Journal of Advances in Nursing Management. 2023; 11(3): 210-4.
8. Akunneh -Wariso C, Aduema W. Comparative Hypoglycemic effects of aqueous leaf extracts of Vernonia amygdalina, Ocimum gratissimum, Phyllanthus amarus, Gongronema latifolum, Piper nigrum and Solanum melongena on Blood Glucose Level of Alloxan-Induced Diabetic Guinea Pigs. Res. J. Pharmacology and Pharmacodynamics. 2019; 11(2): 55-61.
9. Tadesse Waktola Gamessa, Dabbu Suman. Non-Invasive Blood Glucose Monitoring using Visible Laser Light. Research J. Pharm. and Tech. 2019; 2(2): 831-840.
10. Veena Prabavathy J, Sangeetha. R. Stress Induced Type 2 Diabetes Mellitus among Industrial Workers – A Review. Research J. Pharm. and Tech. 2019; 12(1): 396-402.
11. Hoy, Sheridan M. Bexagliflozin: first approval. Drugs. 2023; 83(5): 447-453.
12. IDF. IDF Diabetes Atlas. 9th ed. USA: IDF; 2019. Available from: https://diabetesatlas.org/en. [Last accessed on 2021 Apr 02].
13. Giruzzi et al., Megan, and Ashley Worthey. Bexagliflozin. Clinical Diabetes. 42.1 (2024): 169-171.
14. Zhang W et al., Welihinda A, Mechanic J, EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats. Pharmacol Res. 2011; 63(4): 284–293.
15. Halvorsen YD et al., Lock JP, Frias JP, Tinahones FJ, Dahl D, Conery AL, A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes Obes Metab 2023; 25: 293-301.
16. www.fda.gov-Bexagliflozin
17. Dholariya, Sagar. Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis. Expert Opinion on Pharmacotherapy. 24.18 (2023): 2187-2198.
18. Scheen AJ. Efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. P.g no 33–59
19. Shurraw S et al., Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, Manns B, Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: A population-based cohort study. Arch Intern Med. 2011; 171: 1920-7.
20. Cowart et al., Kevin, Scott Coon, and Nicholas W. Carris. A Review of the Safety and Efficacy of Bexagliflozin for the Management of Type 2 Diabetes. Annals of Pharmacotherapy. 2023: 10600280231190443.
21. Allegretti AS et al. Zhang W, Zhou W, Thurber TK, Rigby SP, Bowman-Stroud C, et al. Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a/3b CKD. Am J Kidney Dis. 2019; 74: 328-37.
22. Dalal, Deepak. A systematic overview of bexagliflozin: A type 2 diabetic drug. Asian Journal of Pharmaceutical Research and Health Care. 2023; 15(2): 109-114.
23. https://clinicaltrials.gov/